New Indicator For Liver Cancer Screening PIVKA-II IVD Products Tumor Maker Assay For Clinical In Vitro Diagnostic

^{_{Clinical Significance}}

^{_{In recent years, a large number of clinical studies have shown that PIVKA-II has good sensitivity and specificity, so PIVKA-IIP is gradually used as an indicator for liver cancer screening and diagnosis in clinical diagnosis.}}

^{_{Abnormal prothrombin increased, seen in more than 90% of hepatocellular carcinoma, the average can be as high as 900μg/L. APT elevation was also seen in 40% to 50% of metastatic liver cancers, but the mean value was lower.
In hepatocellular carcinoma with low alpha-fetoprotein (AFP) levels, APT tends to be elevated. It has been reported that for liver cancer with AFP lower than 400 μg/L, APT was higher than 300 μg/L in 57% of cases. Therefore, simultaneous detection of AFP and APT can improve the diagnosis rate of low-AFP HCC from 48% to 68%. In addition, mildly elevated APT is also seen in chronic hepatitis and vitamin K deficiency, which can be corrected with vitamin K supplementation at this time.}}

^{_{Prothrombin is the precursor of thrombin, and abnormal prothrombin refers to prothrombin synthesized by liver cells in the absence of vitamin K. The normal value of abnormal prothrombin should be less than 20μg/L. Abnormal prothrombin can be used as an indicator for judging hepatocellular carcinoma. When suffering from hepatocellular carcinoma, it will affect the generation of prothrombin precursor, resulting in a large amount of abnormal thrombin. Abnormal prothrombin, alpha-fetoprotein and other tests are commonly used in clinical practice, as well as pathological examinations to clarify the nature of the lesions.}}